Search results
Results from the WOW.Com Content Network
Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. [8] The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, [ 9 ] [ 10 ] [ 11 ] and the EUA was revoked in April 2021.
In February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID-19.
In January 2021, the United States agreed to purchase 1.25 million doses of the drug for $2.625 billion, at $2,100 per dose. [29] [30] On 14 September, another 1.4 million doses were purchased for the same price, totaling $2.94 billion. [31] In January 2021, the German government purchased 200,000 doses for €400 million at €2,000 per dose. [32]
For premium support please call: 800-290-4726 more ways to reach us
The Philippines has among Asia's highest numbers of coronavirus infections, which rose to 136,638 on Monday after a record daily jump of 6,958 cases. Philippines' Duterte has 'huge trust' in ...
The Philippines has received 100,000 doses of the Sinopharm BIBP vaccine from the United Arab Emirates. [102] The Philippines has received a donation of about 1,000,000 doses of the Sinopharm BIBP vaccine on August 20–21 from China. [103] [104] The Philippines has expressed its intent to get some of Canada's COVID-19 vaccines. [105]
The first dose was administered on 22 March and by April 4, the 48,000 participants had received their first dose, [30] [31] and second doses started being administered from April 5. [ 32 ] [ better source needed ] Third doses have started being administered on 19 April [ 33 ] [ 34 ] [ 35 ] and on May 1, adherence to the three-dose protocol was ...
A total of 1,268 healthy participants between the age of 18 and 80 years to be selected from 15 sites across India for the trial and intended to be part of a larger global Phase III study. [ 15 ] [ 13 ] On 3 June 2021, India's Ministry of Health and Family Welfare pre-ordered 300 million doses.